Smits Maarten L J, Bruijnen Rutger C G, Tetteroo Philip, Vonken Evert-Jan P A, Meijerink Martijn R, Hagendoorn Jeroen, de Bruijne Joep, Prevoo Warner
Department of Radiology and Nuclear Medicine, University Medical Center Utrecht, Utrecht, The Netherlands.
Department of Radiology, Amsterdam University Medical Center, Amsterdam, The Netherlands.
Cardiovasc Intervent Radiol. 2023 Oct;46(10):1365-1374. doi: 10.1007/s00270-023-03545-4. Epub 2023 Sep 13.
We present a technique that combines Hepatic Arteriography with C-arm CT-Guided Ablation (HepACAGA) to improve tumor visualization, navigation and margin confirmation for percutaneous ablation of liver tumors.
All consecutive patients scheduled for HepACAGA between April 20th, 2021, and November 2nd, 2021, were included in this retrospective, cohort study. HepACAGA was performed in an angiography-suite under general anesthesia. The hepatic artery was catheterized for selective contrast injection. C-arm CT and guidance software were then used to visualize the tumor and the microwave antenna was inserted during apnea. Pre- and post-ablation C-arm CTs were performed and ablation margins assessed. Technical success, antenna placement deviation, number of repositions, tumor recurrence, and safety were evaluated. Technical success was defined as a tumor that was ablated according to the HepACAGA technique.
A total of 21 patients (28 tumors) were included. The main tumor type was colorectal cancer liver metastases (11/21, 52%), followed by hepatocellular carcinoma (7/21, 33%), neuroendocrine tumor metastases (1/21, 5%), and other tumor types (2/21, 10%). The technical success rate was 93% (26/28 tumors) with two small hypovascular lesions unable to be identified. A single microwave antenna was used in all patients. The median antenna placement deviation was 1 mm (range 0-6 mm). At a median follow-up time of 16 months (range 5-22 months), there was no tumor recurrence in any patient. Safety analysis showed a complication rate of 5% grade 2 and 5% grade 3.
HepACAGA was demonstrated to be a safe and effective percutaneous ablation technique, without any local tumor recurrence in this study.
我们介绍一种将肝动脉造影与C形臂CT引导下消融术(HepACAGA)相结合的技术,以改善肝脏肿瘤经皮消融时的肿瘤可视化、导航及边缘确认。
2021年4月20日至2021年11月2日期间所有计划接受HepACAGA的连续患者纳入本回顾性队列研究。HepACAGA在全身麻醉下于血管造影室进行。经肝动脉插管进行选择性造影剂注射。然后使用C形臂CT和引导软件对肿瘤进行可视化,并在屏气期间插入微波天线。在消融前和消融后进行C形臂CT检查,并评估消融边缘。评估技术成功率、天线放置偏差、重新定位次数、肿瘤复发情况及安全性。技术成功定义为按照HepACAGA技术对肿瘤进行了消融。
共纳入21例患者(28个肿瘤)。主要肿瘤类型为结直肠癌肝转移(11/21,52%),其次为肝细胞癌(7/21,33%)、神经内分泌肿瘤转移(1/21,5%)和其他肿瘤类型(2/21,10%)。技术成功率为93%(26/28个肿瘤),有两个小的乏血供病变未能识别。所有患者均使用单个微波天线。天线放置偏差的中位数为1毫米(范围0 - 6毫米)。中位随访时间为16个月(范围5 - 22个月),所有患者均无肿瘤复发。安全性分析显示2级并发症发生率为5%,3级并发症发生率为5%。
在本研究中,HepACAGA被证明是一种安全有效的经皮消融技术,无任何局部肿瘤复发。